Cardioprotective effect of resveratrol in a postinfarction heart failure model

Adam Riba, Laszlo Deres, B. Sümegi, K. Tóth, Eszter Szabados, R. Halmosi

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Despite great advances in therapies observed during the last decades, heart failure (HF) remained a major health problem in western countries. In order to further improve symptoms and survival in patients with heart failure, novel therapeutic strategies are needed. In some animal models of HF resveratrol (RES), it was able to prevent cardiac hypertrophy, contractile dysfunction, and remodeling. Several molecular mechanisms are thought to be involved in its protective effects, such as inhibition of prohypertrophic signaling molecules, improvement of myocardial Ca2+ handling, regulation of autophagy, and the reduction of oxidative stress and inflammation. In our present study, we wished to further examine the effects of RES on prosurvival (Akt-1, GSK-3β) and stress signaling (p38-MAPK, ERK 1/2, and MKP-1) pathways, on oxidative stress (iNOS, COX-2 activity, and ROS formation), and ultimately on left ventricular function, hypertrophy and fibrosis in a murine, and isoproterenol-(ISO-) induced postinfarction heart failure model. RES treatment improved left ventricle function, decreased interstitial fibrosis, cardiac hypertrophy, and the level of plasma BNP induced by ISO treatment. ISO also increased the activation of P38-MAPK, ERK1/2Thr183-Tyr185, COX-2, iNOS, and ROS formation and decreased the phosphorylation of Akt-1, GSK-3β, and MKP-1, which were favorably influenced by RES. According to our results, regulation of these pathways may also contribute to the beneficial effects of RES in HF.

Original languageEnglish
Article number6819281
JournalOxidative Medicine and Cellular Longevity
Volume2017
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Heart Failure
Glycogen Synthase Kinase 3
Oxidative stress
Cardiomegaly
p38 Mitogen-Activated Protein Kinases
Oxidative Stress
Fibrosis
Phosphorylation
Autophagy
Left Ventricular Hypertrophy
Therapeutics
Medical problems
Left Ventricular Function
Isoproterenol
Heart Ventricles
Animals
Animal Models
Chemical activation
resveratrol
Inflammation

ASJC Scopus subject areas

  • Biochemistry
  • Ageing
  • Cell Biology

Cite this

Cardioprotective effect of resveratrol in a postinfarction heart failure model. / Riba, Adam; Deres, Laszlo; Sümegi, B.; Tóth, K.; Szabados, Eszter; Halmosi, R.

In: Oxidative Medicine and Cellular Longevity, Vol. 2017, 6819281, 01.01.2017.

Research output: Contribution to journalArticle

@article{237484abdf1b48d0a2f9d1a60feefa66,
title = "Cardioprotective effect of resveratrol in a postinfarction heart failure model",
abstract = "Despite great advances in therapies observed during the last decades, heart failure (HF) remained a major health problem in western countries. In order to further improve symptoms and survival in patients with heart failure, novel therapeutic strategies are needed. In some animal models of HF resveratrol (RES), it was able to prevent cardiac hypertrophy, contractile dysfunction, and remodeling. Several molecular mechanisms are thought to be involved in its protective effects, such as inhibition of prohypertrophic signaling molecules, improvement of myocardial Ca2+ handling, regulation of autophagy, and the reduction of oxidative stress and inflammation. In our present study, we wished to further examine the effects of RES on prosurvival (Akt-1, GSK-3β) and stress signaling (p38-MAPK, ERK 1/2, and MKP-1) pathways, on oxidative stress (iNOS, COX-2 activity, and ROS formation), and ultimately on left ventricular function, hypertrophy and fibrosis in a murine, and isoproterenol-(ISO-) induced postinfarction heart failure model. RES treatment improved left ventricle function, decreased interstitial fibrosis, cardiac hypertrophy, and the level of plasma BNP induced by ISO treatment. ISO also increased the activation of P38-MAPK, ERK1/2Thr183-Tyr185, COX-2, iNOS, and ROS formation and decreased the phosphorylation of Akt-1, GSK-3β, and MKP-1, which were favorably influenced by RES. According to our results, regulation of these pathways may also contribute to the beneficial effects of RES in HF.",
author = "Adam Riba and Laszlo Deres and B. S{\"u}megi and K. T{\'o}th and Eszter Szabados and R. Halmosi",
year = "2017",
month = "1",
day = "1",
doi = "10.1155/2017/6819281",
language = "English",
volume = "2017",
journal = "Oxidative Medicine and Cellular Longevity",
issn = "1942-0900",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Cardioprotective effect of resveratrol in a postinfarction heart failure model

AU - Riba, Adam

AU - Deres, Laszlo

AU - Sümegi, B.

AU - Tóth, K.

AU - Szabados, Eszter

AU - Halmosi, R.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Despite great advances in therapies observed during the last decades, heart failure (HF) remained a major health problem in western countries. In order to further improve symptoms and survival in patients with heart failure, novel therapeutic strategies are needed. In some animal models of HF resveratrol (RES), it was able to prevent cardiac hypertrophy, contractile dysfunction, and remodeling. Several molecular mechanisms are thought to be involved in its protective effects, such as inhibition of prohypertrophic signaling molecules, improvement of myocardial Ca2+ handling, regulation of autophagy, and the reduction of oxidative stress and inflammation. In our present study, we wished to further examine the effects of RES on prosurvival (Akt-1, GSK-3β) and stress signaling (p38-MAPK, ERK 1/2, and MKP-1) pathways, on oxidative stress (iNOS, COX-2 activity, and ROS formation), and ultimately on left ventricular function, hypertrophy and fibrosis in a murine, and isoproterenol-(ISO-) induced postinfarction heart failure model. RES treatment improved left ventricle function, decreased interstitial fibrosis, cardiac hypertrophy, and the level of plasma BNP induced by ISO treatment. ISO also increased the activation of P38-MAPK, ERK1/2Thr183-Tyr185, COX-2, iNOS, and ROS formation and decreased the phosphorylation of Akt-1, GSK-3β, and MKP-1, which were favorably influenced by RES. According to our results, regulation of these pathways may also contribute to the beneficial effects of RES in HF.

AB - Despite great advances in therapies observed during the last decades, heart failure (HF) remained a major health problem in western countries. In order to further improve symptoms and survival in patients with heart failure, novel therapeutic strategies are needed. In some animal models of HF resveratrol (RES), it was able to prevent cardiac hypertrophy, contractile dysfunction, and remodeling. Several molecular mechanisms are thought to be involved in its protective effects, such as inhibition of prohypertrophic signaling molecules, improvement of myocardial Ca2+ handling, regulation of autophagy, and the reduction of oxidative stress and inflammation. In our present study, we wished to further examine the effects of RES on prosurvival (Akt-1, GSK-3β) and stress signaling (p38-MAPK, ERK 1/2, and MKP-1) pathways, on oxidative stress (iNOS, COX-2 activity, and ROS formation), and ultimately on left ventricular function, hypertrophy and fibrosis in a murine, and isoproterenol-(ISO-) induced postinfarction heart failure model. RES treatment improved left ventricle function, decreased interstitial fibrosis, cardiac hypertrophy, and the level of plasma BNP induced by ISO treatment. ISO also increased the activation of P38-MAPK, ERK1/2Thr183-Tyr185, COX-2, iNOS, and ROS formation and decreased the phosphorylation of Akt-1, GSK-3β, and MKP-1, which were favorably influenced by RES. According to our results, regulation of these pathways may also contribute to the beneficial effects of RES in HF.

UR - http://www.scopus.com/inward/record.url?scp=85031945490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031945490&partnerID=8YFLogxK

U2 - 10.1155/2017/6819281

DO - 10.1155/2017/6819281

M3 - Article

C2 - 29109832

AN - SCOPUS:85031945490

VL - 2017

JO - Oxidative Medicine and Cellular Longevity

JF - Oxidative Medicine and Cellular Longevity

SN - 1942-0900

M1 - 6819281

ER -